CLAIMS

We claim:

1. A compound of Formula (I):

$$R^{5}$$
 R^{4}
 R^{3}
 R^{1}

(I)

or a salt, solvate, or physiologically functional derivative thereof: wherein:

D is C-R and X is N, or

D is N and X is C-R, or

D is C-R and X is C-R,

where each R is independently selected from hydrogen, halo, cyano, or C_1 - C_6 alkyl;

 R^1 is a group defined by $-(Q)_m-(Q^1)_n-(Q^2)_p$, wherein;

Q is arylene or heteroarylene, and m is 0 or 1,

 Q^1 is $O(CH_2)_q$, $(CH_2)_r$ C(O), or $S(O)_2$, and

n is 0 or 1,

q is 0, 1, 2, 3, or 4, and

r is 1, 2, 3, or 4,

 Q^2 is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, -OH, C_1 - C_3 alkoxy, NR^6R^7 , aryl, aryloxy, heteroaryl, heterocyclyl, or R^9R^{10} , and p is 0 or 1 R^2 is -H, or C_1 - C_6 alkyl; or

R¹ and R² together with the nitrogen to which they are attached form a ring system, said ring system being a substituted or unsubstituted heterocyclyl or heterocyclic spiro ring system;

 R^3 is -H or C_1 - C_3 alkyl;

 R^4 is -H or C_1 - C_3 alkyl;

R⁵ is -H, halo, -CN, -OH, C₁-C₃ alkyl, C₁-C₃alkoxy, -NO₂, aryl, or NR'R";

 R^6 is -H or C_1 - C_6 alkyl;

 R^7 is -H, C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, $-R^9R^{10}$, aralkyl, heterocyclyl, or -C(O) R^8 ;

R⁸ is hydrogen or C₁₋C₆ alkyl;

R⁹ is C₁₋C₆ alkylene or heterocyclylene;

 R^{10} is C_1 - C_6 alkoxy, aryl, aralkyl, heteroaryl, aryloxy, heterocyclyl, -C(O)OR⁸, -C(O)R⁸, or -C(O)NR'R";

R' is -H or C_{1} - C_{6} alkyl;

Н.

R" is -H, C_1 - C_6 alkyl, -C(O)R", -S(O)₂R", or C(O)NHR"; and

R''' is C_1 - C_6 alkyl, aryl, aralkyl, heteroaryl, or heterocyclyl.

- 2. A compound as claimed in claim 1, wherein D is N.
- 3. A compound as claimed in claim 1, wherein D is C-R and R is H.
- 4. A compound as claimed in claim 1, wherein X is N.
- 5. A compound as claimed in claim 1, wherein X is C-R and R is H.
- 6. A compound as claimed in claim 1, wherein D is N, X is C-R, and R is
- 7. A compound as claimed in claim 1, wherein D is C–R, R is H, and X is N.

- 8. A compound as claimed in claim 1, wherein X is C-R, D is C-R, and each R is H.
- 9. A compound as claimed in claim 1, wherein m and n are 0, p is 1 and R^1 is $-(Q^2)$.
- 10. A compound as claimed in claim 1, wherein m and p are 1, n is 0 and R^1 is $-(Q)-(Q^2)$.
- 11. A compound as claimed in claim 1, wherein m, n, and p are 1, and R^1 is $-(Q)-(Q^1)-(Q^2)$.
- 12. A compound as claimed in claim 1, wherein m and p are 1 and Q is arylene.
- 13. A compound as claimed in claim 1, wherein m and p are 1 and Q is heteroarylene.
- 14. A compound as claimed in claim 1, wherein n and p are 1 and Q^1 is $O(CH_2)_q$, where q is 0, 1, 2, 3, or 4.
- 15. A compound as claimed in claim 1, wherein n and p are 1 and Q^1 is $(CH_2)_r$ and where r is 1, 2, 3, or 4.
- 16. A compound as claimed in claim 1, wherein n and p are 1 and Q^1 is C(O).
- 17. A compound aas claimed in claim 1, wherein n and p are 1 and Q^1 is $S(O)_2$.

- 18. A compound as claimed in claim 1, wherein p is 1 and Q^2 is NR^6R^7 .
- 19. A compound as claimed in claim 1, wherein p is 1 and Q^2 is heteroaryl.
- 20. A compound as claimed in claim 1, wherein p is 1 and Q^2 is aryl.
- 21. A compound as claimed in claim 1, wherein p is 1 and Q^2 is R^9R^{10} .
- 22. A compound as claimed in claim 1, wherein R^2 is C_1 - C_6 alkyl.
- 23. A compound as claimed in claim 1, wherein R² is methyl.
- 24. A compound as claimed in claim 1, wherein R^2 is -H.
- 25. A compound as claimed in claim 1, wherein R^3 is C_1 - C_6 alkyl.
- 26. A compound as claimed in claim 1, wherein R³ is methyl.
- 27. A compound as claimed in claim 1, wherein R^3 is -H.
- 28. A compound as claimed in claim 1, wherein R^4 is C_1 - C_6 alkyl.
- 29. A compound as claimed in claim 1, wherein R⁴ is methyl.
- 30. A compound as claimed in claim 1, wherein R⁴ is -H.
- 31. A compound as claimed in claim 1, wherein R^5 is -H, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, or halo.
- 32. A compound as claimed in claim 1, wherein R^5 is -H.

- 33. A compound as claimed in claim 1, wherein R^6 is -H or C_1 - C_6 alkyl.
- 34. A compound as claimed in claim 1, wherein R^6 is -H.
- 35. A compound as claimed in claim 1, wherein R^7 is C_1 - C_6 alkyl.
- 36. A compound as claimed in claim 1, wherein R⁷ is methyl, ethyl or isopropyl.
- 37. A compound as claimed in claim 1, wherein R^7 is aralkyl.
- 38. A compound as claimed in claim 1, wherein R^7 is benzyl.
- 39. A compound as claimed in claim 1, wherein R^7 is R^9R^{10} .
- 40. A compound as claimed in claim 1, selected from the group consisting of:
- (2E)-N-(1,3-benzothiazol-6-yl)-3-(1H-indazol-3-yl)-2-propenamide;
- (2E)-N-(3,4-dimethyl-5-isoxazolyl)-3-(1H-indazol-3-yl)-2-propenamide;
- (2E)-N-(2-cyanophenyl)-3-(1H-indazol-3-yl)-2-propenamide;
- (2E)-3-(1H-indazol-3-yl)-N-(6-methoxy-3-pyridinyl)-2-propenamide;
- (2E)-N-(3-chlorophenyl)-3-(1H-indazol-3-yl)-2-propenamide;
- (2E)-N-(2,3-dihydro-1H-inden-5-yl)-3-(1H-indazol-3-yl)-2-propenamide;
- (2E)-N-[4-(dimethylamino)phenyl]-3-(1H-indazol-3-yl)-2-propenamide;
- (2E)-N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-3-(1H-indazol-3-yl)-2-propenamide;

- (2E)-3-(1H-indazol-3-yl)-N-(5-quinolinyl)-2-propenamide;
- (2E)-N-[3-(acetylamino)phenyl]-3-(1H-indazol-3-yl)-2-propenamide;
- (2E)-3-(1H-indazol-3-yl)-N-(3,4,5-trimethoxyphenyl)-2-propenamide;
- (2E)-N-(3-benzoylphenyl)-3-(1H-indazol-3-yl)-2-propenamide;
- (2*E*)-*N*-[3-chloro-4-(4-morpholinyl)phenyl]-3-(1*H*-indazol-3-yl)-2-propenamide;
- (2E)- N- $\{5-[(diethylamino)sulfonyl]-2-methoxyphenyl\}-3-<math>(1H$ -indazol-3-yl)-2-propenamide;
- (2E)-N- $\{4-[2-(diisopropylamino)ethoxy]$ - $3-methoxyphenyl\}$ -3-(1H-indazol-3-yl)-2-propenamide;
- (2*E*)-3-(1H-indazol-3-yl)-N-(3-methoxy-4-{2-[(2-phenoxyethyl) amino]ethoxy} phenyl)-2-propenamide;
- (2*E*)-3-(1H-indazol-3-yl)-N-{3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl}-2-propenamide;
- (2*E*)-3-(1H-indazol-3-yl)-N-(3-methoxy-4-{2-[(2-methoxyethyl)amino]-ethoxy}phenyl)-2-propenamide;
- (2*E*)-3-(1H-indazol-3-yl)-N-(3-methoxy-4-{2-[methyl(propyl)amino]ethoxy}phenyl)-2-propenamide;
- (2E)-N-[4- $(2-{[2-(4-chlorophenyl)ethyl]amino}ethyoxy)-3-methoxyphenyl]-3-<math>(1H-indazol-3-yl)-2-propenamide;$
- ethyl 4-{[2-(4-{[(2E)-3-(1H-indazol-3-yl)-2-propenoyl]amino}-2-methoxyphenoxy) ethyl]amino}-1-piperidine carboxylate;
- (2E)-N- $\{4-[2-(4-acetyl-1-piperazinyl)ethoxy]-3-methoxyphenyl\}-3-<math>\{1H-indazol-3-yl\}$ -2-propenamide;
- (2*E*)-*N*-benzyl-3-(1*H*-indazol-3-yl)prop-2-enamide;
- (2*E*)-3-(1*H*-indazol-3-yl)-*N*-isobutylprop-2-enamide;
- (2E)-3-(1H-indazol-3-yl)-N-(3-morpholin-4-ylpropyl)prop-2-enamide;

- (2*E*)-*N*-[2-(4-chlorophenyl)ethyl]-3-(1*H*-indazol-3-yl)prop-2-enamide;
- ethyl 1-\((2E)-3-(1H-indazol-3-yl)\)prop-2-enoyl\]piperidine-4-carboxylate;
- 3-[(1*E*)-3-(4-benzylpiperidin-1-yl)-3-oxoprop-1-enyl]-1*H*-indazole;
- (2E)-N-ethyl-3-(1H-indazol-3-yl)-N-(pyridin-4-ylmethyl)prop-2-enamide;
- 8-[(2*E*)-3-(1*H*-indazol-3-yl)prop-2-enoyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

...

- 3-[(1*E*)-3-oxo-3-(4-pyrazin-2-ylpiperazin-1-yl)prop-1-enyl]-1*H*-indazole;
- methyl 4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)benzoate;
- 4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)benzoic acid;
- methyl 3-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)benzoate;
- 3-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)benzoic acid;
- 4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-(2-pyridin-3-ylethyl)benzamide;
- 4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-methyl-N-(2-pyridin-2-ylethyl)benzamide;
- 4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide;
- 3-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-(2-morpholin-4-ylethyl)benzamide;
- (2E)-N-(3-((4-benzylpiperazin-1-yl)carbonyl)phenyl)-3-(1H-indazol-3-yl)prop-2-enamide; and
- N-ethyl-3-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-(pyridin-4-ylmethyl)benzamide
- or a salt, solvate, or physiologically functional derivative thereof.
- 41. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 to 40, or a salt,

solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

- 42. A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate SGK-1 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 40, or a salt, solvate, or a physiologically functional derivative thereof.
- 43. A compound as claimed in any of claims 1 to 40, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.
- 44. Use of a compound as claimed in any of claims 1 to 40, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate SGK-1 activity.